RESEARCH ARTICLE

Association between plasma xanthine oxidoreductase activity and in-hospital outcomes in patients with stable coronary artery disease after percutaneous coronary intervention

Ryota Sato1, Keitaro Akita1, Takenori Ikoma1, Keisuke Iguchi1, Takayo Murase2, Takashi Nakamura2, Seigo Akari2, Satoshi Mogi1, Yoshihisa Naruse2,1, Hayato Ohtani1, Yuichiro Maekawa*1

1 Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan, 2 Sanwa Kagaku Kenkyusho Co., Ltd., Aichi, Japan

* ymaekawa@hama-med.ac.jp

Abstract

Objectives

Reactive oxygen species generated by xanthine oxidoreductase (XOR) are associated with the progression of atherosclerosis. However, changes in plasma XOR (pXOR) activity after percutaneous coronary intervention (PCI) for stable coronary artery disease (CAD) remains unknown.

Methods

Herein, we compared the change in the pXOR activity in patients undergoing PCI with that in patients undergoing coronary angiography (CAG) and further evaluated the relation between changes in pXOR activity and in-hospital and long-term outcomes of patients undergoing PCI. The pXOR activity of 80 consecutive patients who underwent PCI and 25 patients who underwent CAG during the hospitalization was analyzed daily. The percentage changes from baseline regulated time interval was evaluated.

Results

We found that although pXOR activity decreased after PCI, and remained low until discharge, no significant changes were observed in patients undergoing CAG. Furthermore, among the patients undergoing PCI, those who experienced in-hospital adverse events, had a higher percentage of pXOR reduction 3 days after PCI. There was no association between these changes and long-term events.
Conclusions
A significant change in pXOR activity was observed in patients undergoing PCI than in patients undergoing CAG, and there seems to be a correlation between the in-hospital outcomes and the percentage reduction from baseline in pXOR activity.

1. Introduction
Oxidative stress is one of the risk factors of coronary artery disease (CAD), which affects the prognosis and reduces the survival time and quality of life of patients [1–3]. Characterized by an imbalance between the generation of reactive oxygen species (ROS) and the capacity of the intrinsic antioxidant defense system, it has been implicated in the pathogenesis of cardiovascular diseases [3]. Increased activity of xanthine oxidoreductase (XOR) is known to reportedly increase the production of both ROS and uric acid [4]. An increase in ROS production, results in oxidative stress-mediated myocardial and arterial vessel injury [5]. A technique for measuring plasma XOR (pXOR) activity was recently established, and several reports have been published regarding pXOR activity in patients with chronic heart failure and heart and renal diseases [6, 7] as well as in healthy populations [8, 9]. Although the association between single assessments of pXOR activity and cardiovascular diseases and metabolic disorders has been elucidated, changes in pXOR activity, obtained by repeated measurements, after percutaneous coronary intervention (PCI) for stable CAD, remains unknown. Therefore, we aimed to evaluate the daily pXOR activity in hospitalized patients with CAD before and after PCI and investigate the association between the changes in pXOR activity and the in-hospital and long-term outcomes.

2. Materials and methods
2.1 Study design
This study was a prospective single-center study. The study protocol complied with the guidelines of the Institutional Ethics Committee, and all the participants provided written, informed consent for participation in the study, as well as publication of their data.

2.2 Participants
Participants were recruited from Hamamatsu University hospital between October 2017 and December 2020. Elective coronary angiography (CAG) was performed in patients with typical angina or suspected stable CAD whose clinical characteristics and results of noninvasive testing or significant stenosis observed on coronary computed tomography indicated a high likelihood of CAD. The exclusion criteria of CAG were as follows: 1) acute coronary syndrome, 2) receiving hemodialysis, 3) post coronary artery bypass graft or 4) left ventricular ejection fraction <50%. The indications for PCI in this study were as follows: 1) Patients in whom the perfusion zone of the coronary artery with significant stenosis (American Heart Association classification >75%) coincided with the area of ischemia demonstrated by noninvasive ischemia evaluation test or 2) Patients with moderate stenosis (50–75% stenosis) or multi-vessel lesions demonstrated by CAG and ischemia by fractional flow reserve (FFR), but with a vessel diameter that allows drug-eluting stent implantation. FFR evaluation was performed following procedures previously described [10]. The exclusion criteria of PCI included acute coronary syndrome, receiving hemodialysis or PCI failure. A total of 105 patients were enrolled of
which 25 underwent elective CAG and 80 underwent PCI. Plasma XOR activity was measured daily in all the 105 subjects undergoing CAG or PCI over 3 days of hospitalization. All patients undergoing CAG or PCI were hospitalized for 3 nights unless more hospitalization days were required at the physician’s discretion. All patients had a follow-up evaluation at a clinical visit at 8 months. The percentage change in pXOR activity was defined as:

\[
\text{% change} = \frac{(\text{pXOR activity after CAG or PCI} - \text{pXOR activity before CAG or PCI})}{\text{pXOR activity before CAG or PCI}} \times 100
\]

based on the time course of the plasma XOR activity during the hospitalization.

2.3 CAG and PCI procedures
We used a previously described procedure for PCI [11]. Patients were administered 100 mg aspirin and 75 mg clopidogrel or 3.75 mg prasugrel orally before the scheduled PCI. CAG was performed in all patients using a 5F catheter via a radial approach [12]. Conventional methods involving the use of a guiding catheter, a 0.014-inch guidewire, and a monorail balloon catheter were used for stent deployment. The type of drug-eluting stents used was at the operator’s discretion. After stent implantation, further balloon upsizing and/or higher inflation pressures were used. Platelet glycoprotein IIb/IIIa inhibitors were not used in this study.

2.4 Clinical assessments
Baseline characteristics of all patients were recorded. The presence of coronary risk factors, including smoking habits, hypertension, diabetes mellitus (DM), chronic kidney disease (CKD), defined as estimated GFR (eGFR) < 60 mL/min/1.73 m², a family history of premature CAD, defined as myocardial infarction (MI) or sudden death in a first relative, male younger than 55 years or female younger than 65 years; and concomitant medications including aspirin, clopidogrel, prasugrel, beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium antagonists, and XOR inhibitors, were reviewed [11]. Further, we investigated the incidence of in-hospital and long-term outcomes including all-cause death, periprocedural MI, cardiogenic shock, stroke, a new requirement for hemodialysis, a need for blood transfusion, and major bleeding. Periprocedural MI was defined according to an expert consensus document from the Society for Cardiovascular Angiography and Interventions [13]. Major bleeding was defined as the occurrence of Bleeding Academic Research Consortium type 3 or 5 bleeding [14]. A composite in-hospital adverse event was defined as the occurrence of all-cause death, periprocedural MI, stroke, and major bleeding.

2.5 Laboratory methods
2.5.1 Plasma XOR activity. Blood samples were collected in a blood collection tube coated with ethylenediaminetetraacetic acid (EDTA)-2K kept at 4°C until centrifugation and centrifuged by 2,000 g at 4°C for 10 min to separate plasma. The pXOR activity was measured by liquid chromatography/triple quadrupole mass spectrometry (LC/TQMS) (Nexera HLC, SHIMADZU, Japan/QTRAP 4500, SCIEX) to detect \(^{13}\text{C}_2\text{,}^{15}\text{N}_2\) uric acid using \(^{13}\text{C}_2\text{,}^{15}\text{N}_2\) xanthine as a substrate as previously reported [15-17].

2.5.2 Concentrations of hypoxanthine and xanthine. Blood samples were collected using a blood collection tube coated with PAX-gene DNA, kept at 4°C until centrifugation and centrifuged at 2,000 g at 4°C for 10 min to separate plasma. Plasma concentrations of hypoxanthine and xanthine were measured as previously reported [18]. In brief, plasma samples were added into methanol containing \(^{13}\text{C}_2\text{,}^{15}\text{N}_2\) xanthine and \(^{13}\text{C}_3\text{,}^{15}\text{N}_3\) hypoxanthine as internal standard and were centrifuged at 3,000 g at 4°C for 15 min. The supernatant (40 μL) was
diluted with 160 μL of distilled water and concentrations of hypoxanthine and xanthine measured using LC/TQMS.

2.5.3 Statistical analysis. Continuous data including pXOR activity, which are not normally distributed are presented as median and lower upper quartile. The other continuous variables are expressed as mean ± SD if they are normally distributed. The normality of distribution of each variable was tested using the Shapiro-Wilk W test. Categorical variables are expressed as absolute values and percentages. For comparisons between CAG and PCI groups or between patients undergoing PCI with and without adverse events, the Mann–Whitney U-test (non-parametric), t-test (parametric) and Fisher’s exact test or chi-square test (categorical) were used as appropriate. Within-group comparisons of a percent reduction in pXOR activity from baseline at different time points were performed using the Mann–Whitney U-test. The Wilcoxon rank-sum test was used to evaluate the changes in pXOR activity between before and 3 days after PCI. The G Power computer program version 3.1.9.2 (Heinrich Heine University, Dusseldorf, Germany) [19] was used to calculate a priori sample size required for the Wilcoxon rank-sum test. It would be modeled at an effect size of 0.5 (medium), α level of 0.05 and power of 0.80, and a minimum of 50 participants would be required. All P values were 2-sided, and results were considered statistically significant at a P value <0.05. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria, version 2.13.0). More precisely, it is a modified version of R command (version 1.27) that was designed to add statistical functions frequently used in biostatistics.

3. Results

Our study population included 105 patients with CAD, of which 25 had undergone CAG and 80 had undergone PCI. Baseline characteristics of both groups of patients are shown in Table 1. The age, proportion of male, and BMI were similar between the CAG and PCI groups. There were no significant differences in the prevalence of the coronary risk factors including hypertension, DM, dyslipidemia, and smoking between the both groups. Low density lipoprotein-cholesterol levels were lower in patients undergoing PCI than in patients undergoing CAG. There were no significant differences in pXOR activity as well as in the levels of uric acid, xanthine, and hypoxanthine between the groups. As for the medication, the use of aspirin and prasugrel was higher in the PCI group than in the CAG group.

3.1 Time course of plasma XOR activity

Plasma XOR activity decreased after PCI and remained low until the discharge of the patients. On the other hand, no significant change was observed in patients undergoing CAG. Fig 1 shows the percentage reduction in pXOR activity at each time point from baseline in patients undergoing CAG and PCI. Compared with CAG group, a significant decrease in the percent pXOR activity from baseline at day 1 and day 2 were observed in the PCI group.

3.2 Association of the percentage reduction in plasma XOR activity with the in-hospital outcomes

Characteristics of the PCI procedure and details of the in-hospital outcomes are shown in Table 2. Patients who experienced adverse in-hospital outcomes had a longer total fluoroscopy time and procedure time, and larger volume of the contrast dose (Table 2). The incidence of periprocedural MI was higher in patients undergoing PCI with in-hospital adverse events than in patients without in-hospital adverse events (Table 2). The percentage reduction of pXOR...
### Table 1. Baseline characteristics.

| Characteristics          | CAG (n = 25) | PCI (n = 80) | P value |
|--------------------------|--------------|--------------|---------|
| Age, years, mean (SD)    | 73.5 (8.4)   | 70.2 (10.0)  | 0.140   |
| Male, n (%)              | 19 (76.0)    | 59 (73.8)    | 1       |
| BMI, kg/m², mean (SD)    | 24.8 (3.6)   | 23.4 (3.9)   | 0.110   |
| Hypertension, n (%)      | 21 (84.0)    | 53 (66.2)    | 0.131   |
| DM, n (%)                | 14 (56.0)    | 37 (46.2)    | 0.493   |
| Dyslipidemia, n (%)      | 17 (68.0)    | 46 (57.5)    | 0.484   |
| CKD, n (%)               | 17 (68.0)    | 43 (53.8)    | 0.252   |
| Smoking, n (%)           | 1 (4.0)      | 10 (12.5)    | 0.453   |
| Family history of CAD, n (%) | 0 (0.0)  | 3 (3.8)      | 1       |
| Hyperuricemia, n (%)     | 5 (20.0)     | 11 (13.8)    | 0.525   |
| Previous MI, n (%)       | 12 (48.0)    | 33 (41.2)    | 0.645   |
| Previous CVD, n (%)      | 5 (20.0)     | 5 (6.2)      | 0.055   |
| Previous PAD, n (%)      | 2 (8.0)      | 12 (15.0)    | 0.51    |
| Previous AF/AFL, n (%)   | 2 (8.0)      | 10 (12.5)    | 0.727   |
| Medications              |              |              |         |
| Aspirin, n (%)           | 21 (84.0)    | 80 (100.0)   | 0.003   |
| Clopidogrel, n (%)       | 3 (12.0)     | 21 (26.2)    | 0.178   |
| Prasugrel, n (%)         | 10 (40.0)    | 58 (72.5)    | 0.004   |
| ACE-inhibitor/ARBs, n (%)| 18 (72.0)    | 45 (56.2)    | 0.242   |
| β blockers, n (%)        | 16 (64.0)    | 54 (67.5)    | 0.81    |
| Statin, n (%)            | 22 (88.0)    | 72 (90.0)    | 0.721   |
| Ca channel blockers, n (%) | 16 (64.0) | 29 (36.2)    | 0.02    |
| Diuretics, n (%)         | 3 (12.0)     | 14 (17.5)    | 0.757   |
| XOR inhibitor, n (%)     | 3 (12.0)     | 11 (13.8)    | 0.664   |
| Insulin, n (%)           | 4 (16.0)     | 10 (12.5)    | 0.737   |
| Oral antidiabetic drugs, n (%) | 7 (28.0) | 22 (27.5)    | 1       |
| DOAC, n (%)              | 2 (8.0)      | 8 (10.0)     | 1       |
| Warfarin, n (%)          | 1 (4.0)      | 0 (0.0)      | 0.238   |
| Echocardiography         |              |              |         |
| LVEF (Teichholz) %, mean (SD) | 60.7 (9.8) | 53.3 (14.9)  | 0.155   |
| LVDd, mm, mean (SD)      | 49.9 (4.8)   | 47.6 (6.4)   | 0.355   |
| LVDs, mm, mean (SD)      | 33.3 (4.0)   | 34.4 (7.3)   | 0.703   |
| Laboratory data          |              |              |         |
| LDL-C, mg/dL, mean (SD)  | 88.8 (23.8)  | 73.5 (22.7)  | 0.005   |
| HbA1c, %, mean (SD)      | 6.9 (0.99)   | 6.5 (1.0)    | 0.104   |
| Uric acid, mg/dL, mean (SD) | 5.5 (1.7) | 5.6 (1.6)    | 0.63    |
| XOR activity, pmol/h/ml plasma, median (IQR) | 31.70 [7.59, 182.00] | 44.65 [0.00, 738.00] | 0.064 |
| Xanthine, μM, median (IQR) | 0.42 [0.25, 22.60] | 0.64 [0.15, 17.30] | 0.14    |
| Hypoxanthine, μM, median (IQR) | 3.58 [0.83, 15.60] | 3.69 [0.70, 63.80] | 0.633   |

Abbreviations: CAG, coronary angiography; PCI, percutaneous coronary intervention; SD, standard deviation; BMI, body mass index; DM, diabetes mellitus; CKD, chronic kidney disease; CAD, coronary artery disease; MI, myocardial infarction; CVD, cerebrovascular disease; PAD, peripheral artery disease; AF/AFL, atrial fibrillation/atrial flutter; ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor blockers; XOR, xanthine oxidoreductase; DOAC, direct oral anti-coagulants; LVEF, left ventricular ejection fraction; LVDd, left ventricular end diastolic diameter; LVDs, left ventricular end systolic diameter; LDL-C, low density lipoprotein-cholesterol; HbA1C, hemoglobin A1C; IQR, interquartile range.

https://doi.org/10.1371/journal.pone.0257227.t001
activity at day 3 in patients undergoing PCI with in-hospital adverse events was higher than in patients without in-hospital adverse events (Fig 2).

3.3 Long-term outcomes

The mean duration of follow-up was 11 ± 8 months. During follow-up, a total of 5 patients experienced a non-cardiac adverse event. At 8 months follow-up, there was no significant difference of percentage reduction of pXOR activity at day 3 between patients with and without long-term adverse events (Fig 3).

4. Discussion

This study demonstrated that 1) compared with CAG group, a significant decrease in the percent pXOR activity from baseline at day 1 and day 2 were observed in the PCI group, and 2) larger percentage reduction of pXOR activity after PCI from baseline was associated with in-hospital outcomes.

Plasma XOR activity is known to be associated with severity and clinical outcome in chronic heart failure, left ventricular hypertrophy, low left ventricular ejection fraction, coronary artery spasm, and severely decompensated acute heart failure [7, 20–22]. All of these studies indicated an elevated pXOR activity in the patients with cardiac disease suggesting that the severity of these diseases may be attributed to ROS generated by the XOR. However, it is unclear whether invasive procedures used in the treatment of cardiac disease affect pXOR...
activity. This study showed serial changes in pXOR activity in hospitalized patients with stable CAD, undergoing CAG or PCI. The pXOR activity notably decreased after PCI than after CAG, suggesting that PCI may be affecting the pXOR activity by relieving angina and reducing the extent of myocardial ischemia. However, patients with in-hospital adverse events had a higher percentage reduction in pXOR activity than those without in-hospital adverse events. This implies that the influence of a myocardial injury resulting from a longer procedure time is much greater than that of reducing myocardial ischemia, as it produces excessive ROS.

### Table 2. Details of the PCI procedure and in-hospital outcomes.

| Characteristics                  | PCI total (n = 80) | Without AE (n = 72) | With AE (n = 8) | P value |
|----------------------------------|-------------------|---------------------|----------------|---------|
| **Approach site**                |                   |                     |                |         |
| TRI, n (%)                       | 72 (90.0)         | 65 (90.3)           | 7 (87.5)       | 0.587   |
| TFI, n (%)                       | 8 (10.0)          | 7 (9.7)             | 1 (12.5)       |         |
| **Sheath size**                  |                   |                     |                |         |
| 6Fr, n (%)                       | 69 (86.3)         | 63 (87.5)           | 6 (75.0)       | 0.302   |
| 7Fr, n (%)                       | 11 (13.7)         | 9 (12.5)            | 2 (25.0)       |         |
| **Total fluoroscopy time, min, mean (SD)** | 34.5 (25.7)       | 29.5 (16.5)         | 79.88 (46.76)  | <0.001  |
| **Procedure time, min, mean (SD)** | 99.0 (54.5)       | 89.2 (41.1)         | 188.12 (82.29) | <0.001  |
| **Contrast dose, ml, mean (SD)** | 127.4 (56.3)      | 122.7 (53.3)        | 170.00 (71.86) | 0.024   |
| IABP use, n (%)                  | 1 (1.4)           | 1 (1.4)             | 0 (0.0)        | 1       |
| Rotablator use, n (%)            | 7 (8.7)           | 6 (8.3)             | 1 (12.5)       | 0.536   |
| **Stent**                        |                   |                     |                |         |
| PtCr-EES, n (%)                  | 14 (17.5)         | 11 (15.3)           | 3 (37.5)       | 0.555   |
| CoCr-EES, n (%)                  | 37 (46.2)         | 33 (45.8)           | 4 (50.0)       |         |
| R-ZES, n (%)                     | 3 (3.7)           | 3 (4.2)             | 0 (0.0)        |         |
| U-SES, n (%)                     | 22 (27.5)         | 21 (29.2)           | 1 (12.5)       |         |
| Others, n (%)                    | 4 (5.0)           | 4 (5.6)             | 0 (0.0)        |         |
| **Number of diseased vessels**   |                   |                     |                |         |
| 1VD, n (%)                       | 56 (70.0)         | 52 (72.2)           | 4 (50.0)       | 0.287   |
| 2VD, n (%)                       | 20 (25.0)         | 16 (22.2)           | 4 (50.0)       |         |
| 3VD, n (%)                       | 4 (5.0)           | 4 (5.6)             | 0 (0.0)        |         |
| **Lesion site**                  |                   |                     |                |         |
| LMT, n (%)                       | 11 (13.7)         | 10 (13.9)           | 1 (12.5)       | 1       |
| LAD, n (%)                       | 44 (55.0)         | 39 (54.2)           | 5 (62.5)       |         |
| LCX, n (%)                       | 12 (15.0)         | 11 (15.3)           | 1 (12.5)       |         |
| RCA, n (%)                       | 13 (16.2)         | 12 (16.7)           | 1 (12.5)       |         |
| **In-hospital outcomes**         |                   |                     |                |         |
| Deaths, n (%)                    | 0 (0.0)           | 0 (0.0)             | 0 (0.0)        | 1       |
| MI, n (%)                        | 6 (7.5)           | 0 (0.0)             | 6 (75.0)       | <0.001  |
| Stroke, n (%)                    | 0 (0.0)           | 0 (0.0)             | 0 (0.0)        | 1       |
| Shock, n (%)                     | 1 (1.3)           | 0 (0.0)             | 1 (12.5)       | 0.1     |
| Hemodialysis, n (%)              | 0 (0.0)           | 0 (0.0)             | 0 (0.0)        | 1       |
| Blood transfusion, n (%)         | 1 (1.3)           | 0 (0.0)             | 1 (12.5)       | 0.1     |
| Major bleeding, n (%)            | 1 (1.3)           | 0 (0.0)             | 1 (12.5)       | 0.1     |

Abbreviations: PCI, percutaneous coronary intervention; AE, adverse events; TRI, transradial intervention; TFI, transfemoral intervention; SD, standard deviation; IABP, intra-aortic balloon pump; EES, everolimus-eluting stent; ZES, zotarolimus-eluting stent; SES, sirolimus-eluting stent; VD, vessel disease; LMT, left main trunk; LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery; MI, myocardial infarction.

https://doi.org/10.1371/journal.pone.0257227.t002
which in turn inhibits the pXOR activity. To the best of our knowledge, none of the previous studies evaluating the repeated measurements of systemic XOR activity, showed elevated or decreased pXOR activity after PCI in stable CAD patients.

In patients with ST-elevation MI, PCI is the most important strategy used to inhibit the ongoing myocardial damage. Paradoxically, although myocardial reperfusion is essential for myocardial salvage, it comes with a price, it can in itself induce myocardial injury and cardiomyocyte death—a phenomenon termed ‘myocardial reperfusion injury’ [23]. The reperfused ischemic myocardium generates ROS. These ROS reduce the bioavailability of nitric oxide, hence affects the myocardial damage. There is no evidence, however, of generating ROS by significantly reducing the narrowing of coronary arteries by PCI. In a previous report, the quantity of total peroxides, which is a marker of oxidative stress levels, showed no significant changes during the first 48 h, while their levels declined to below baseline after 30 days post sirolimus-eluting stent implantation [24]. In our study, patients received a drug-eluting stent implantation and pXOR activity instead of the degree of oxidative stress was serially evaluated, since oxidative stress normally occurs when the balance between ROS production and antioxidant defense capacity is disrupted in favor of the former. The exact redox mechanism of CAD is complex and has not yet been fully determined [25]. In fact, the efficacy of pharmacological interventions targeting both the ROS sources and antioxidants in CAD has been inconclusive. Our study may shed some light on the future therapeutic approaches to redox systems in patients with CAD.

Xanthine oxidoreductase is involved in the production of not only ROS, but also uric acid [26]. Several studies have reported the correlation between elevated plasma uric acid levels and
Meanwhile, low serum uric acid levels were associated with an increased risk of vascular events in men at moderate-to-high cardiovascular disease risk but not in women [29]. Therefore, whether uric acid has a causal relationship in these conditions remains to be determined [30]. The many potential pharmacological cardiovascular benefits of XOR inhibitors include improvement in endothelial function, decrease in tissue oxidative stress, and increase in ATP synthesis in the ischemic tissue [31]. However, the 2019 European Society of Cardiology (ESC) Guidelines for the diagnosis and management of chronic coronary syndromes mentioned that the role of allopurinol, a representative of the XOR inhibitors, in reducing clinical events in CAD remains unclear [32]. We exhibited decreased XOR activity after PCI irrespective of plasma uric acid levels and this may be associated with alleviated myocardial ischemia.

A previous report showed that age, DM, and CKD were associated with a high pXOR activity in outpatients with cardiovascular diseases [33]. Comorbidities including coronary risk factors may influence the baseline pXOR activity in our patients undergoing PCI. That is to say, the background of the patients undergoing PCI was not uniform at the individual level, and therefore, we evaluated the association between the percentage reduction in pXOR activity and in-hospital clinical outcomes instead of assessing the absolute level of pXOR activity. Although the pXOR activity may vary according to patient background, the percent changes in plasma XOR activity may offer superior information regarding the influence of the PCI on pXOR activity.
This study has several limitations. First, the sample size is small although the pXOR activity was measured daily during the hospitalization, implying that several measurements of pXOR activity per patient were required as compared with one-point measurements of pXOR activity. Hence, further investigation is required to clarify the relationship between the change in pXOR activity and in-hospital outcomes. Second, pXOR activity at baseline were higher in patients undergoing PCI than undergoing CAG. Therefore, the percentage reduction of pXOR activity in patients undergoing PCI might be result of a regression to the mean of pXOR activity with alleviated myocardial ischemia by revascularization. Third, to the best of our knowledge, this is the first study to show decreased pXOR activity after PCI in patients with CAD. However, since redox is a complicated process, the mechanism involved in this decrease is unclear, therefore, a verification study should be required to confirm the consistency of the present results.

5. Conclusions
In conclusion, patients with stable CAD, showed a significant decrease in the pXOR activity after PCI than after CAG. Furthermore, it was found that a higher percentage reduction of pXOR activity after PCI was associated with in-hospital outcomes.

Author Contributions
Conceptualization: Yuichiro Maekawa.
Data curation: Ryota Sato, Keitaro Akita, Takenori Ikoma, Keisuke Iguchi, Yuichiro Maekawa.
Formal analysis: Ryota Sato.
Investigation: Ryota Sato, Yuichiro Maekawa.
Methodology: Ryota Sato, Takayo Murase, Takashi Nakamura, Seigo Akari.
Resources: Takayo Murase, Takashi Nakamura, Seigo Akari.
Supervision: Yuichiro Maekawa.
Validation: Yuichiro Maekawa.
Writing – original draft: Ryota Sato, Yuichiro Maekawa.
Writing – review & editing: Takayo Murase, Takashi Nakamura, Seigo Akari, Satoshi Mogi, Yoshihisa Naruse, Hayato Ohtani, Yuichiro Maekawa.

References
1. Harrison D, Griendling KK, Landmesser U, Homig B, Drexler H. Role of oxidative stress in atherosclerosis. The American Journal of Cardiology. 2003; 91(3): 7–11. https://doi.org/10.1016/s0002-9149(02)03144-2 PMID: 12645638
2. Burtenshaw D, Kelch M, Redmond EM, Megson IL, Cahill PA. Reactive Oxygen Species (ROS), Intimal Thickening, and Subclinical Atherosclerotic Disease. Front Cardiovasc Med. 2019; 6: 89. https://doi.org/10.3389/fcvm.2019.00089 eCollection 2019. PMID: 31428618
3. Juni RP, Ducksers HJ, Vanhoutte PM, Virmanni R, Moens AL. Oxidative stress and pathological changes after coronary artery interventions. J Am Coll Cardiol. 2013; 61(14): 1471–1481. https://doi.org/10.1016/j.jacc.2012.11.068 PMID: 2350310
4. Tziomalos K, Hare JM. Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance. Front Biosci (Landmark Ed). 2009; 14: 237–262. https://doi.org/10.2741/3243 PMID: 19273066
5. Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart. 2007; 93(8): 903–907. https://doi.org/10.1136/hrt.2005.068270 PMID: 16670100
6. Nakatani A, Nakatani S, Ishimura E, Murase Y, Nakamura T, Sakura M, et al. Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients. Sci Rep. 2017; 7(1): 15416. doi:10.1038/s41598-017-15419-0 PMID: 29138805

7. Fujimura Y, Yamauchi Y, Murase T, Nakamura T, Fujita S, Fujisaka T, et al. Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients. PLoS One. 2017; 12(8): e0182699. https://doi.org/10.1371/journal.pone.0182699 eCollection 2017. PMID: 28797123

8. Washio KW, Kusunoki Y, Murase T, Nakamura T, Osugi K, Ohigashi M, et al. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young metabolism. 2017; 70: 51–56. https://doi.org/10.1016/j.metabol.2017.01.031 Epub 2017 Feb 4. PMID: 28403945

9. Furuhashi M, Matsumoto M, Tanaka M, Moniwa N, Murase T, Nakamura T, et al. Plasma Xanthine Oxidoreductase Activity as a Novel Biomarker of Metabolic Disorders in a General Population. Circ J. 2018; 82(7): 1892–1899. https://doi.org/10.1253/circj.CJ-18-0082 Epub 2018 Apr 10. PMID: 29643318

10. Kawaguchi Y, Ito K, Kin h, Shirai Y, Okazaki Y, Miyazima K, et al. Impact of Hydrostatic Pressure Variations Caused by Height Differences in Supine and Prone Positions on Fractional Flow Reserve Values in the Coronary Circulation. J Interv Cardiol. 2019; 2019:4532862. https://doi.org/10.1155/2019/4532862 eCollection 2019. PMID: 31772532

11. Sukegawa H, Maekawa Y, Yuasa S, Anzai A, Kodaira M, Takei M, et al. Intensive statin therapy stabilizes C-reactive protein, but not chemokine in stable coronary artery disease treated with an everolimus-eluting stent. Coron Artery Dis 2016; 27(5): 405–411. https://doi.org/10.1097/MCA.0000000000000375 PMID: 27105048

12. Mogi S, Maekawa Y, Kodaira M, Anzai A, Arai T, Kawakami T, et al. Aortic aneurysm: an independent predictor of a looped brachiocephalic trunk in patients undergoing transradial coronary angiography. Coron Artery Dis 2013; 24(7): 602–605. https://doi.org/10.1097/MCA.0b013e3283650294 PMID: 23921234

13. Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013; 62(17): 1563–1570. https://doi.org/10.1016/j.jacc.2013.08.720 PMID: 24153581

14. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123(23): 2736–2747. https://doi.org/10.1161/CIRCULATIONAHA.110.009449 PMID: 21670242

15. Murase T, Nampei M, Oka M, Ashizawa N, Matsumoto K, Miyachi A, et al. Xanthine oxidoreductase activity assay in tissues using stable isotope-labeled substrate and liquid chromatography high-resolution mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2016; 1008: 189–197. https://doi.org/10.1016/j.jchromb.2015.11.030 Epub 2015 Nov 25. PMID: 26673227

16. Murase T, Oka M, Nampei M, Miyachi A, Nakamura T. A highly sensitive assay for xanthine oxidoreductase activity using a combination of [(13) C2, (15) N2] xanthine and liquid chromatography/triple quadrupole mass spectrometry. J Labelled Comp Radiopharm. 2016; 59(5): 214–220. https://doi.org/10.1002/jlqr.3390 Epub 2016 Mar 22. PMID: 27006202

17. Murase T, Nampei M, Oka M, Miyachi A, Nakamura T. A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS. J Chromatogr B Analyt Technol Biomed Life Sci. 2016; 1039: 51–58. https://doi.org/10.1016/j.jchromb.2016.03.033 Epub 2016 Oct 24. PMID: 27816314

18. Furuhashi M, Koyama M, Higashiu Y, Murase T, Nakamura T, Matsumoto M, et al. Differential regulation of hypoxanthine and xanthine by obesity in a general population. J Diabetes Investig 2020; 11: 878–887. https://doi.org/10.1111/jdi.13207 Epub 2020 Feb 9. PMID: 31916414

19. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39:175–191. https://doi.org/10.3758/bf03193146 PMID: 17695343

20. Otaki Y, Watanabe T, Kinoshita D, Yokoyama M, Takahashi T, Toshima T, et al. Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure. Int J Cardiol. 2017; 228: 151–157. https://doi.org/10.1016/j.jcard.2016.11.077 Epub 2016 Nov 9. PMID: 27865177

21. Okazaki H, Shirakabe A, Matsushita M, Shibata Y, Sawatani T, Uchiyama S, et al. Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care. ESC Heart Fail. 2019; 6(2): 336–343. https://doi.org/10.1002/ehf2.12390 Epub 2019 Jan 8. PMID: 30620450
22. Watanabe K, Shishido T, Otaki Y, Watanabe T, Sugai T, Toshima T, et al. Increased plasma xanthine oxidoreductase activity deteriorates coronary artery spasm. Heart Vessels. 2019; 34(1): 1–8. https://doi.org/10.1007/s00380-018-1207-4 Epub 2018 Jun 23. PMID: 29936631

23. Frohlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J. 2013; 34(23): 1714–1722. https://doi.org/10.1093/eurheartj/eht090 Epub 2013 Mar 27. PMID: 23536610

24. Kochiadakis GE, Arfanakis DA, Marketou ME, Skalidis EI, Igoumenidis NE, Nikitovic D, et al. Oxidative stress changes after stent implantation: a randomized comparative study of sirolimus-eluting and bare metal stents. Int J Cardiol. 2010; 142(1): 33–37. https://doi.org/10.1016/j.ijcard.2008.12.105 Epub 2009 Jan 24. PMID: 19168247

25. He F, Zuo L. Redox Roles of Reactive Oxygen Species in Cardiovascular Diseases. Int J Mol Sci. 2015; 16(11): 27770–27780. https://doi.org/10.3390/ijms161126059 PMID: 26610475

26. Yoshida S, Kurajoh M, Fukumoto S, Murase T, Nakamura T, Yoshiha H, et al. Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry. Sci Rep 2020; 10(1): 4437. https://doi.org/10.1038/s41598-020-61463-8 Epub 2020 Mar 23. PMID: 32157204

27. Andrikou I, Tsioulis C, Dimitriadis K, Konstantinidis D, Kasiakogias A, Kouremeti M, et al. Uric acid as an independent predictor of coronary artery disease in essential hypertension: Data from an 8-year-follow-up study. Clin Exp Pharmacol Physiol. 2018; 45(8): 866–869. https://doi.org/10.1111/1440-1681.12926 Epub 2018 Mar 23. PMID: 29489034

28. Tscharre M, Herman R, Rohla M, Hauser C, Farhan S, Freynhofer MK, et al. Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Atherosclerosis. 2018; 270: 173–179. https://doi.org/10.1016/j.atherosclerosis.2018.02.003 Epub 2018 Feb 10. PMID: 29432935

29. Mannarino MR, Pirro M, Gigante B, Savonen K, Kurl S, Giralt P, et al. Association Between Uric Acid, Carotid Intima-Media Thickness, and Cardiovascular Events: Prospective Results From the IMPROVE Study. J Am Heart Assoc. 2021 Jun; 10(11):e020419. https://doi.org/10.1161/JAHA.120.020419 Epub 2021 May 17. PMID: 33998285

30. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008; 359(17): 1811–1821. https://doi.org/10.1056/NEJMr0800885 PMID: 18946066

31. Zdrengha M, Siton-Taut A, Cismaru G, Zdrengha D, Pop D. Xanthine oxidase inhibitors in ischaemic heart disease. Cardiovasc J Afr. 2017; 29(3): 201–204. https://doi.org/10.5830/CVJA-2016-060 Epub 2016 Sep 9. PMID: 27701488

32. Kruutil J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477. https://doi.org/10.1002/ejha.425 PMID: 31504439

33. Matsushita M, Shirakabe A, Okazaki H, Shibata Y, Goda H, Shigihara S, et al. Plasma Xanthine Oxidoreductase (XOR) Activity in Cardiovascular Disease Outpatients. Circulation Reports. 2020; 2(2): 104–112. https://doi.org/10.1253/circrep.CR-19-0116 PMID: 33693315